Helping women with metastatic breast cancer take their medication as prescribed
Improving medication adherence using a CONnected CUstomized Treatment Platform (CONCURxP)
This project helps adult women with a specific type of metastatic breast cancer take their prescribed medication using a special mobile phone platform.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11190894 on NIH RePORTER |
What this research studies
For women with hormone receptor-positive, HER2-negative metastatic breast cancer, taking CDK4/6 inhibitor medications as prescribed is very important for improving survival. However, these medications can have complex schedules and be costly, sometimes making it hard to stick to the plan. This project introduces a personalized mobile health platform called CONCURxP, designed to make it easier for patients to follow their medication schedule. We are comparing this new platform to standard care to see if it helps patients take their medication more consistently. Participants will use a smart pillbox to track their medication intake, and those in the CONCURxP group will also receive customized support through their mobile phones.
Who could benefit from this research
Good fit: Ideal candidates are adult English- or Spanish-speaking women with HR+ HER2- metastatic breast cancer who are starting a new CDK4/6 inhibitor prescription and have a text-enabled mobile phone.
Not a fit: Patients who do not have HR+ HER2- metastatic breast cancer or are not prescribed CDK4/6 inhibitors would not directly benefit from this specific intervention.
Why it matters
Potential benefit: If successful, this platform could help patients with metastatic breast cancer take their life-extending medications more consistently, potentially improving their survival and quality of life.
How similar studies have performed: While mobile health interventions have shown promise in improving medication adherence for various conditions, this specific platform and its impact on CDK4/6i adherence in metastatic breast cancer is being tested in a randomized controlled trial.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Sadigh, Gelareh — University of California-Irvine
- Study coordinator: Sadigh, Gelareh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.